EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients

Andrei Makhon, Sivan Fuchs, Mor Rubinstein, Maya Brodsky, Zeev Dveyrin iD, Noa Tejman-Yarden iD, Yelena Losev

International Journal of Molecular Sciences · 12.03.2026 · 27 (6) · 2597

DOI: 10.3390/ijms27062597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2026. Verfasst von Andrei Makhon und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Public Health Laboratory, Public Health Directorate, Ministry of Health, Tel Aviv 6810416, Israel. Hauptthemen laut MEDLINE: Isoniazid, Mycobacterium tuberculosis, Antitubercular Agents, Extensively Drug-Resistant Tuberculosis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israeli Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid and accurate detection of drug-resistant tuberculosis (DR-TB) is critical for effective treatment and containment. The Xpert® MTB/XDR (GXXDR) assay is designed to detect Mycobacterium tuberculosis complex (MTBC) and resistance to isoniazid and second-line anti-TB drugs directly from clinical specimens. We evaluated the clinical performance of GXXDR using 61 MTBC-positive specimens with available phenotypic drug susceptibility testing results. GXXDR results were compared to a phenotypic drug susceptibility test (pDST) and whole-genome sequencing (WGS) to assess sensitivity, specificity, and concordance. Resistance to isoniazid, fluoroquinolones, amikacin, capreomycin, and ethionamide was analyzed. Sensitivity comparisons between GXXDR, WGS, pDST, and manufacturer data were performed using Fisher’s exact and Tango tests. GXXDR demonstrated a high specificity for most drugs and a strong sensitivity for isoniazid (93.8%) and fluoroquinolone (92.3%), consistent with manufacturer reports. In contrast, the sensitivity for amikacin (58.3%), capreomycin (35.7%), and ethionamide (27.3%) was significantly lower than stated by the manufacturer (91.9%, 84.0% and 64.7%, respectively), likely due to resistance mutations outside the assay’s target regions. Sensitivity concordance of GXXDR with WGS was high for all drugs, except ethionamide. The GXXDR assay enables rapid and reliable detection of isoniazid and fluoroquinolone resistance in clinical settings, though sensitivity for certain second-line drugs may be affected by regional genetic diversity. These findings underscore the importance of integrating local epidemiological data to optimize molecular diagnostics for DR-TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidMycobacterium tuberculosisAntitubercular AgentsExtensively Drug-Resistant TuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsWhole Genome SequencingSensitivity and Specificity

Stichwörter der Autor:innen

Mycobacterium tuberculosis complex (MTBC)Xpert® MTB/XDR (GXXDR)drug resistant TB (DR-TB)extensively drug resistant TB (XDR-TB)whole genome sequencing (WGS)

Substanzen

IsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • National Public Health Laboratory, Public Health Directorate, Ministry of Health, Tel Aviv 6810416, Israel.
  • Clalit Health Services, Regional Laboratory of Haifa and Western Galilee, Nesher 3688847, Israel.

ORCID-Profile: Zeev Dveyrin, Noa Tejman-Yarden

Förderung

  • Israeli Ministry of Health

Zitieren

APA

Makhon, A., Fuchs, S., Rubinstein, M., Brodsky, M., Dveyrin, Z., Tejman-Yarden, N., & Losev, Y. (2026). Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. International Journal of Molecular Sciences, 27(6), 2597. https://doi.org/10.3390/ijms27062597

Vancouver

Makhon A, Fuchs S, Rubinstein M, Brodsky M, Dveyrin Z, Tejman-Yarden N, et al. Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. International Journal of Molecular Sciences. 2026;27(6):2597. doi:10.3390/ijms27062597

BibTeX
@article{Makhon2026,
  author = {Makhon, Andrei and Fuchs, Sivan and Rubinstein, Mor and Brodsky, Maya and Dveyrin, Zeev and Tejman-Yarden, Noa and Losev, Yelena},
  title = {Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {2597},
  doi = {10.3390/ijms27062597}
}
Kostenlos starten →